Metformin as Potential Therapy for High-Grade Glioma.
Marek MazurekJakub LitakPiotr KamieniakBartłomiej KuleszaKatarzyna JonakJacek BajCezary GrochowskiPublished in: Cancers (2020)
Metformin (MET), 1,1-dimethylbiguanide hydrochloride, is a biguanide drug used as the first-line medication in the treatment of type 2 diabetes. The recent years have brought many observations showing metformin in its new role. The drug, commonly used in the therapy of diabetes, may also find application in the therapy of a vast variety of tumors. Its effectiveness has been demonstrated in colon, breast, prostate, pancreatic cancer, leukemia, melanoma, lung and endometrial carcinoma, as well as in gliomas. This is especially important in light of the poor options offered to patients in the case of high-grade gliomas, which include glioblastoma (GBM). A thorough understanding of the mechanism of action of metformin can make it possible to discover new drugs that could be used in neoplasm therapy.
Keyphrases
- high grade
- low grade
- prostate cancer
- end stage renal disease
- randomized controlled trial
- type diabetes
- systematic review
- ejection fraction
- healthcare
- chronic kidney disease
- newly diagnosed
- acute myeloid leukemia
- emergency department
- stem cells
- metabolic syndrome
- risk assessment
- replacement therapy
- mesenchymal stem cells
- glycemic control
- cell therapy
- skeletal muscle
- weight loss
- insulin resistance